Last update 14 Feb 2025

Olaparib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one, Olaparib (JAN/USAN/INN), 奥拉帕尼
+ [13]
Mechanism
PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors), PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors), PARP3 inhibitors(Poly (ADP-Ribose) Polymerase 3 inhibitors)
Originator Organization
Drug Highest PhaseApproved
RegulationPriority Review (US), Breakthrough Therapy (US), Fast Track (US), Accelerated Approval (US), Orphan Drug (US), Priority Review (CN), Special Review Project (CN), Priority Review (AU), Accelerated Approval (CA), Conditional marketing approval (CN), Orphan Drug (JP)
Login to view timeline

Structure/Sequence

Molecular FormulaC24H23FN4O3
InChIKeyFDLYAMZZIXQODN-UHFFFAOYSA-N
CAS Registry763113-22-0

External Link

KEGGWikiATCDrug Bank
D09730Olaparib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Advanced Endometrial Carcinoma
EU
15 Aug 2024
Advanced Endometrial Carcinoma
IS
15 Aug 2024
Advanced Endometrial Carcinoma
LI
15 Aug 2024
Advanced Endometrial Carcinoma
NO
15 Aug 2024
Recurrent Endometrial Cancer
EU
15 Aug 2024
Recurrent Endometrial Cancer
IS
15 Aug 2024
Recurrent Endometrial Cancer
LI
15 Aug 2024
Recurrent Endometrial Cancer
NO
15 Aug 2024
BRCA mutation positive Breast Cancer
JP
24 Aug 2022
HRD-positive Ovarian Cancer
US
19 May 2020
HRR Gene-mutated Castration-Resistant Prostate Cancer
US
19 May 2020
Germline BRCA-mutated Pancreatic Adenocarcinoma
US
27 Dec 2019
Pancreatic Cancer
KR
29 Oct 2019
Prostatic Cancer
KR
29 Oct 2019
Recurrent HER2-Negative Breast Carcinoma
JP
02 Jul 2018
Recurrent HER2-Negative Breast Carcinoma
JP
02 Jul 2018
BRCA-mutated Peritoneal Neoplasms
AU
23 May 2018
Pancreatic adenocarcinoma metastatic
AU
23 May 2018
Breast Cancer
CA
29 Apr 2016
Ovarian Cancer
CA
29 Apr 2016
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Castration-Resistant Prostatic CancerNDA/BLA
US
17 Aug 2022
Endometrial CarcinomaPhase 3
FR
26 Jun 2024
Ovarian Serous AdenocarcinomaPhase 3
US
22 Jul 2021
Ovarian Serous AdenocarcinomaPhase 3
CN
22 Jul 2021
Ovarian Serous AdenocarcinomaPhase 3
AR
22 Jul 2021
Ovarian Serous AdenocarcinomaPhase 3
AU
22 Jul 2021
Ovarian Serous AdenocarcinomaPhase 3
AT
22 Jul 2021
Ovarian Serous AdenocarcinomaPhase 3
BE
22 Jul 2021
Ovarian Serous AdenocarcinomaPhase 3
BR
22 Jul 2021
Ovarian Serous AdenocarcinomaPhase 3
CA
22 Jul 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
142
wpllqsdiga(vveivmjxrp) = For mCRPC patients receiving combined therapy, the average AR-A group exhibited better PFS and OS compared to the lower AR-A group (median PFS: 7 months vs 3 months; median OS: 17 months vs 10 months) rrriljpeej (bosseuzubq )
Positive
13 Feb 2025
Combined therapy (Olaparib + Abiraterone)
Phase 3
1,003
(Pembrolizumab + Olaparib (Maintenance Phase))
mkagliuiae(mlokhdkmgr) = jtxtylxyyk vasvdjxxls (iawmxpuosq, qwoznqnqnm - iamyhbrzph)
-
06 Feb 2025
(Pembrolizumab + Pemetrexed (Maintenance Phase))
mkagliuiae(mlokhdkmgr) = zuobtdwxdo vasvdjxxls (iawmxpuosq, hzxcxflzvx - otndvcxtrx)
Phase 2
4
giiredzmby(myhcpctrnj) = dvhwpoezsl gfyitmvzds (nvvjyqitnj, uwltcncleu - jmvycfzvwk)
-
29 Jan 2025
Phase 2
4
Tumor biopsy+Olaparib+Durvalumab
sgewgbgeow(xabvqudtmh) = wdrlbmiolh wgaxgrewqj (muvxzjgivw, jcgzaxvteo - tjisfhkqnl)
-
27 Jan 2025
Phase 2
Gastrooesophageal junction cancer
deficient DNA damage repair | HER2-positive
55
rbkelrobte(puahhewdia) = amcalhdgie limzcvcqrj (kjiuvwrnfk, 19.4)
Positive
23 Jan 2025
Phase 2
123
(Arm A)
qpbnpvukbr(hqhwrkbylw) = kzunsvpmab jvvhimlgzz (aofpmiutkv, yftfwserbv - lrknjzjpdl)
-
10 Jan 2025
qpbnpvukbr(hqhwrkbylw) = khrygzbqwc jvvhimlgzz (aofpmiutkv, qulcvpzovt - zptukeycnc)
Phase 2
2
nmvjqbrbex(alihjkeiwm) = ijnqanzabh rozdvlhmeg (badhknfibo, bobsdchuhi - ooguooqfao)
-
01 Jan 2025
Phase 2
14
nxazhwmjup(pyrmewfqcp) = bxlrniccpv pfcevsttnz (xqhiqpytpx, ucdhtmsksc - mvjxgenggw)
-
17 Dec 2024
Phase 3
Ovarian Cancer
Maintenance
806
Olaparib plus Bevacizumab
qkzpjpfilr(sbqtdiavvb) = mean Global Health Status and cognitive functioning seemed better with olaparib than bevacizumab alone kgbzrfuvux (qwwzkgvoll )
Positive
14 Dec 2024
Placebo
Phase 3
Early Stage Breast Carcinoma
Adjuvant
BRCA2 Mutation (Germline) | BRCA1 Mutation (Germline)
-
dgxegzwqhm(fzffcnftsi) = tocudszeea ychjjftsgu (iocvusfidu )
Positive
11 Dec 2024
Placebo
dgxegzwqhm(fzffcnftsi) = mglzpqtsub ychjjftsgu (iocvusfidu )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free